Fluselenamyl: A novel benzoselenazole derivative for pet detection of amyloid plaques (Aβ) in Alzheimer's disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Sundaram, G S M ^a,b   Dhavale, Dhruva D ^a   Prior, Julie L ^a,b   Yan, Ping ^a   Cirrito, John ^a,c   Rath, Nigam P ^d   Laforest, Richard ^b   Cairns, Nigel J ^a,c   Lee, Jin Moo ^a,b,e   Kotzbauer, Paul T ^a   Sharma, Vijay ^a,b,e  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^e WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ORGANOSELENIUM DERIVATIVE; PROTEIN BINDING;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL; AUTORADIOGRAPHY; BINDING SITE; BRAIN; CEREBROSPINAL FLUID; CHEMISTRY; DIAGNOSTIC IMAGING; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; SYNTHESIS; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; AUTORADIOGRAPHY; BINDING SITES; BIOMARKERS; BRAIN; MICE; MICE, TRANSGENIC; ORGANOSELENIUM COMPOUNDS; PLAQUE, AMYLOID; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROTEIN BINDING;

EID: 84994339395     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35636     Document Type: Article

References (62)

1. Ferri, C. P., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117 (2005
2. Cummings, J. L. Biomarkers in Alzheimer?s disease drug development. Alzheimer?s & dementia: the journal of the Alzheimer?s Association 7, e13-e44, doi: 10.1016/j.jalz.2010.06.004 (2011
3. Teipel, S. J., Buchert, R., Thome, J., Hampel, H., & Pahnke, J. Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-Transgene expression. Prog. Neurobiol. 95, 547-556, doi: 10.1016/j. pneurobio.2011.05.004 (2011
4. Prvulovic, D., & Hampel, H. Amyloid beta (Abeta), and phospho-Tau (p-Tau) as diagnostic biomarkers in Alzheimer?s disease. Clin. Chem. Lab. Med. 49, 367-374, doi: 10.1515/CCLM.2011.087 (2011
5. Hampel, H., et al. Biomarkers for Alzheimer?s disease therapeutic trials. Prog. Neurobiol. 95, 579-593, doi: 10.1016/j. pneurobio.2010.11.005 (2011
6. Price, J. L., et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 30, 1026-1036, doi: 10.1016/j.neurobiolaging.2009.04.002 (2009
7. Klunk, W., et al. Imaging brain amyloid in Alzheimer?s disease with Pittsburgh Compound-B. Ann. Neurol 55, 306-319 (2004
8. Shin, J., Kepe, V., Barrio, J. R., & Small, G. W. The merits of FDDNP-PET imaging in Alzheimer?s disease. Journal of Alzheimer?s disease: JAD 26 Suppl 3, 135-145, doi: 10.3233/JAD-2011-0008 (2011
9. Verhoeff, N., et al. In vivo imaging of Alzheimer disease β-Amyloid with [13C]SB-13 PET. Am. J. Geriatr. Psychiatry 12, 584-595 (2004
10. Choi, S. R., et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med. 50, 1887-1894, doi: 10.2967/jnumed.109.065284 (2009
11. Rowe, C. C., et al. Head-To-head comparison of 11C-PiB, and 18F-AZD4694 (NAV4694) for beta-Amyloid imaging in aging, and dementia. J. Nucl. Med. 54, 880-886, doi: 10.2967/jnumed.112.114785 (2013
12. Cselenyi, Z., et al. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J. Nucl. Med. 53, 415-424, doi: 10.2967/jnumed.111.094029 (2012
13. Nordberg, A. PET imaging of amyloid in Alzheimer?s disease. Lancet neurology 3, 519-527 (2004
14. Maya, Y., et al. Preclinical properties, and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloidbeta. Brain 139, 193-203, doi: 10.1093/brain/awv305 (2016
15. Chen, C. J., et al. In vivo SPECT imaging of amyloid-beta deposition with radioiodinated imidazo[1, 2-A]pyridine derivative DRM106 in a mouse model of Alzheimer?s disease. J. Nucl. Med. 56, 120-126, doi: 10.2967/jnumed.114.146944 (2015
16. Hsiao, I. T., et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging 39, 613-620, doi: 10.1007/s00259-011-2051-2 (2012
17. Koole, M., et al. Whole-body biodistribution, and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J. Nucl. Med. 50, 818-822, doi: 10.2967/jnumed.108.060756 (2009
18. Nelissen, N., et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers, and patients with probable Alzheimer disease. J. Nucl. Med. 50, 1251-1259, doi: 10.2967/jnumed.109.063305 (2009
19. Rowe, C. C., et al. Imaging of amyloid beta in Alzheimer?s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet neurology 7, 129-135, doi: 10.1016/S1474-4422(08)70001-2 (2008
20. Villemagne, V. L., et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease, and other dementias. J. Nucl. Med. 52, 1210-1217, doi: 10.2967/jnumed.111.089730 (2011
21. Becker, G. A., et al. PET quantification of 18F-florbetaben binding to beta-Amyloid deposits in human brains. J. Nucl. Med. 54, 723-731, doi: 10.2967/jnumed.112.107185 (2013
22. Wong, D F., et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapircorrected] F 18). J. Nucl. Med 51 913-920 10.2967/jnumed.109.069088 2010
23. Ni, R., Gillberg, P. G., Bergfors, A., Marutle, A., & Nordberg, A. Amyloid tracers detect multiple binding sites in Alzheimer?s disease brain tissue. Brain 136, 2217-2227, doi: 10.1093/brain/awt142 (2013
24. Lockhart, A., et al. Evidence for presence of three distinct binding sites for thioflavin T class of Alzheimer?s disease PET imaging agents on β-Amyloid peptide fibrils. J. Biol. Chem. 280, 7677-7684 (2005
25. Sundaram, G., et al. Characterization of a brain permeant fluorescent molecule, and visualization of Aβ parenchymal plaques, using real-Time multiphoton imaging in transgenic mice. Org. Lett. 16, 3640-3643 (2014
26. Sundaram, G., Cairns, N., Lee, J.-M., & Sharma, V. Design, and synthesis of a novel PET probe for early detection of Alzheimer?s disease. J. Nucl. Med. 55, 137 (2014
27. Sundaram, G. S., et al. Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Abeta (beta-Amyloid) plaques in Alzheimer?s disease. EJNMMI research 5, 112, doi: 10.1186/s13550-015-0112-4 (2015
28. Fujiwara, S., Asanuma, Y., Shin-ike, T., & Kambe, N. Copper(I)-catalyzed highly efficient synthesis of benzoselenazoles, and benzotellurazoles. J. Org. Chem. 72, 8087-8090, doi: 10.1021/jo7013164 (2007
29. Redon, S., Kabri, Y., Crozet, M., & Vanelle, P. One pot preparation of 2-(alkyl)arylbenzoselenazoles from the coressponding N-(acetyl)benzoyl-2-iodoanilines via a microwave assisted methodology. Tet Lett 55, 5052-5054 (2014
30. Yu, K., Park, J., & Yang, S. Synthesis of [18F]Fluorocholine analogues as potential imaging agents for PET studies. Bull Korean Chem Soc 25, 506-510 (2004
31. Carrera, I., et al. Vaccine Development to Treat Alzheimer?s Disease Neuropathology in APP/PS1 Transgenic Mice. International journal of Alzheimer?s disease 2012, 376138, doi: 10.1155/2012/376138 (2012
32. Tanifum, E. A., et al. Intravenous delivery of targeted liposomes to amyloid-beta pathology in APP/PSEN1 transgenic mice. PloS one 7, e48515, doi: 10.1371/journal.pone.0048515 (2012
33. DeMattos, R., O'dell, M., Parsadanian, M., Holtzman, D., et al. Clusterin promotes amyloid plaque formation, and is critical for neuritic toxicity in a mouse model of Alzheimer?s disease. Proc Natl Acad Sci USA 99, 10843-10848 (2002
34. Cirrito, J. R., et al. Serotonin signaling is associated with lower amyloid-beta levels, and plaques in transgenic mice, and humans. Proc. Natl. Acad. Sci. USA 108, 14968-14973, doi: 10.1073/pnas.1107411108 (2011
35. Mirra, S., et al. The Consortium to Establish a Registry for Alzheimer?s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer?s disease. Neurology 41, 479-486 (1991
36. Hyman, B., & Trojanowski, J. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging, and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 56, 1095-1097 (1997
37. Cairns, N. J., Taylor-Reinwald, L., & Morris, J. C. Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core. Alzheimer?s & dementia: the journal of the Alzheimer?s Association 6, 274-279, doi: 10.1016/j.jalz.2010.03.012 (2010
38. Mathis, C. A., Mason, N. S., Lopresti, B. J., & Klunk, W. E. Development of positron emission tomography beta-Amyloid plaque imaging agents. Semin. Nucl. Med. 42, 423-432, doi: 10.1053/j.semnuclmed.2012.07.001 (2012
39. Bagchi, D. P., et al. Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility, and screening approaches for developing a Parkinson disease imaging agent. PloS one 8, e55031, doi: 10.1371/journal.pone.0055031 (2013
40. Highlights of prescribing information for Neuraceq (Florbetaben). http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204677s000lbl.pdf (2014
41. Choi, S. R., et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Abeta aggregation, and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis. Assoc. Disord. 26, 8-16, doi: 10.1097/WAD.0b013e31821300bc (2012
42. Brown, P. Pharmacology/toxicology NDA review, and evaluation for Vizamyl (Flutemetamol). http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/203137Orig1s000PharmR.pdf (2013
43. Johnson, A. E., et al. AZD2184: a radioligand for sensitive detection of beta-Amyloid deposits. J. Neurochem. 108, 1177-1186, doi: 10.1111/j.1471-4159.2008.05861.x (2009
44. Matsumura, K., et al. Structure-Activity Relationship Study of Heterocyclic Phenylethenyl, and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimer?s Disease Brains. J. Med. Chem. 58, 7241-7257, doi: 10.1021/acs.jmedchem.5b00440 (2015
45. Mathis, C., et al. Synthesis, and evaluation of 11C-labeled 6-substituted 2-Arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 46, 2740-2754 (2003
46. Brockschnieder, D., et al. Preclinical characterization of a novel class of 18F-labeled PET tracers for amyloid-beta. J. Nucl. Med. 53, 1794-1801, doi: 10.2967/jnumed.112.104810 (2012
47. Dischino, D., Welch, M., Kilbourn, M., & Raichle, M. Relationship between lipophilicity, and brain extraction of C-11 labeled radiopharmaceuticals. J Nucl Med 24, 1030-1038 (1983
48. Quillard, T., & Libby, P. Molecular imaging of atherosclerosis for improving diagnostic, and therapeutic development. Circ. Res. 111, 231-244, doi: 10.1161/CIRCRESAHA.112.268144 (2012
49. Dong, J., Revilla-Sanchez, R., Moss, S., & Haydon, P. G. Multiphoton in vivo imaging of amyloid in animal models of Alzheimer?s disease. Neuropharmacology 59, 268-275, doi: 10.1016/j.neuropharm.2010.04.007 (2010
50. Janus, C., Chishti, M. A., & Westaway, D. Transgenic mouse models of Alzheimer?s disease. Biochim. Biophys. Acta 1502, 63-75 (2000
51. F, v. L. Single, and multiple transgenic mice as models for Alzheimer?s disease. Prog. Neurobiol 61, 305-312 (2000
52. Holtzman, D., Bales, K., Tenkova, T., Paul, S., et al. Apolipoprotein E isoform-dependent amyloid deposition, and neuritic degeneration in a mouse model of Alzheimer?s disease. Proc Natl Acad Sci USA 97, 2892-2897 (2000
53. Gotz, J. Tau, and transgenic animal models. Brain Res. Brain Res. Rev. 35, 266-286 (2001
54. Crews, L., Rockenstein, E., & Masliah, E. APP transgenic modeling of Alzheimer?s disease: mechanisms of neurodegeneration, and aberrant neurogenesis. Brain structure & function 214, 111-126, doi: 10.1007/s00429-009-0232-6 (2010
55. Kurt, M. A., et al. Neurodegenerative changes associated with beta-Amyloid deposition in the brains of mice carrying mutant amyloid precursor protein, and mutant presenilin-1 transgenes. Exp. Neurol. 171, 59-71, doi: 10.1006/exnr.2001.7717 (2001
56. Bacskai, B., et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice. Proc Natl Acad Sci USA 100, 12462-12467 (2003
57. Brendel, M., et al. Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models. PloS one 10, e0116678, doi: 10.1371/journal.pone.0116678 (2015
58. Maeda, J., et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-Amyloid treatment in a living mouse model of Alzheimer?s disease enabled by positron emission tomography. J. Neurosci. 27, 10957-10968, doi: 10.1523/JNEUROSCI.0673-07.2007 (2007
59. Manook, A., et al. Small-Animal PET imaging of amyloid-beta plaques with [11C]PiB, and its multi-modal validation in an APP/PS1 mouse model of Alzheimer?s disease. PloS one 7, e31310, doi: 10.1371/journal.pone.0031310 (2012
60. Rominger, A., et al. Longitudinal assessment of cerebral beta-Amyloid deposition in mice overexpressing Swedish mutant betaamyloid precursor protein using 18F-florbetaben PET. J. Nucl. Med. 54, 1127-1134, doi: 10.2967/jnumed.112.114660 (2013
61. Snellman, A., et al. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J. Nucl. Med. 54, 1434-1441, doi: 10.2967/jnumed.112.110163 (2013
62. Snellman, A., et al. In vivo PET imaging of beta-Amyloid deposition in mouse models of Alzheimer?s disease with a high specific activity PET imaging agent [(18)F]flutemetamol. EJNMMI research 4, 37, doi: 10.1186/s13550-014-0037-3 (2014